Literature DB >> 11426953

Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study.

J P Dhar1, D Kmak, R Bhan, L Pishorodi, J Ager, R J Sokol.   

Abstract

OBJECTIVE: The aim of this study was to review Pap smear reports in women with systemic lupus erythematosus and compare them to a large control population.
METHODS: Pap smear results of 29 women with a diagnosis of lupus seen consecutively were compared to those of a control population of 747 women attending the gynecology clinic at the same medical center during the same year. Records of lupus patients were reviewed to obtain clinical data. Fisher's exact test and chi(2) analysis were used to determine statistical significance, as appropriate.
RESULTS: Of 29 women with lupus, 1/29 had high-grade squamous intraepithelial lesions (HGSIL) and 6/29 had low-grade squamous intraepithelial lesions (LGSIL). The control population of 747 women had 9/747 with HGSIL and 63/747 with LGSIL. chi(2) and Fisher's exact tests showed that the lupus population had a statistically significant increase in Pap smear reports of dysplasia compared to the control group (P < 0.021 for HGSIL/LGSIL combined, P < 0.036 for LGSIL alone). Examination of serial Pap smear results revealed that 45% of the lupus patients had cervical dysplasia at some time.
CONCLUSION: Women with lupus have an increased prevalence of cervical dysplasia. Serial observation revealed dysplastic cytologies in nearly half of the patients, suggesting that this may be a more common problem than previously reported. Serial prospective studies are needed to assess better the risk of premalignant cervical lesions in lupus. Copyright 2001 Academic Press.

Entities:  

Mesh:

Year:  2001        PMID: 11426953     DOI: 10.1006/gyno.2001.6207

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

Review 2.  Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 3.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

4.  Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus.

Authors:  Leomar D C Lyrio; Maria Fernanda R Grassi; Iuri U Santana; Viviana G Olavarria; Aline do N Gomes; Licia CostaPinto; Rone Peterson C Oliveira; Rita de Cássia R Aquino; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

Review 5.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 6.  Malignancies in systemic lupus erythematosus.

Authors:  Emese Kiss; Laszlo Kovacs; Peter Szodoray
Journal:  Autoimmun Rev       Date:  2009-07-27       Impact factor: 9.754

7.  The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus.

Authors:  J Patricia Dhar; Lynnette Essenmacher; Renee Dhar; Ardella Magee; Joel Ager; Robert J Sokol
Journal:  Hum Vaccin Immunother       Date:  2018-06-08       Impact factor: 3.452

8.  Stage one adenocarcinoma of uterine cervix in a patient with systemic lupus erythematosus - a clinical case.

Authors:  Latchezar Tantchev; Angel Yordanov; Veselin Marinov; Andrey Kotzev
Journal:  Prz Menopauzalny       Date:  2021-01-07

9.  Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years.

Authors:  Arzu Soybilgic; Karen B Onel; Tammy Utset; Kenneth Alexander; Linda Wagner-Weiner
Journal:  Pediatr Rheumatol Online J       Date:  2013-08-07       Impact factor: 3.054

10.  The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus.

Authors:  Claudia Mendoza-Pinto; Mario Garcia-Carrasco; Veronica Vallejo-Ruiz; Alejandro Taboada-Cole; Margarita Muñoz-Guarneros; Juan Carlos Solis-Poblano; Elias Pezzat-Said; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suarez; Luis Vazquez de Lara; Gloria Ramos-Alvarez; Julio Reyes-Leyva; Aurelio Lopez-Colombo
Journal:  Clinics (Sao Paulo)       Date:  2013-12       Impact factor: 2.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.